Can prostate cancer be NICE?


Journal

Clinical radiology
ISSN: 1365-229X
Titre abrégé: Clin Radiol
Pays: England
ID NLM: 1306016

Informations de publication

Date de publication:
Nov 2019
Historique:
received: 09 05 2019
accepted: 14 06 2019
pubmed: 22 7 2019
medline: 9 6 2020
entrez: 21 7 2019
Statut: ppublish

Résumé

On 9 May 2019, the National Institute for Health and Care Excellence (NICE) published its updated UK guidance on prostate cancer. The publication is the culmination of a 3 year process. It is an evidence-based, carefully crafted, comprehensive "book" to compliment the pre-existing 2014 guidance. It was born from new evidence on aspects of prostate cancer treatment and, most relevant for this special edition, diagnosis. This article provides a "behind-the-scenes" on how NICE operates, using the guideline as a case study. The piece sets out to demystify this august governance body's processes: from the decision to update the existing guidance, through the scoping and discussion stages to the principles and policies that shaped the whole process. This provides the backdrop to the second half of the article wherein the 85 page guideline is condensed in to a few highly pertinent recommendations. The areas that sparked the most debate during the committee's 24-month lifespan are highlighted, finishing by asking the UK radiology community: where do we go next in this new era of multiparametric magnetic resonance imaging first?

Identifiants

pubmed: 31324338
pii: S0009-9260(19)30299-5
doi: 10.1016/j.crad.2019.06.009
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

823-830

Commentaires et corrections

Type : CommentIn
Type : CommentIn

Informations de copyright

Copyright © 2019. Published by Elsevier Ltd.

Auteurs

J Richenberg (J)

Department of Imaging, Brighton & Sussex University Hospitals NHS Trust, Eastern Road, Brighton BN2 5BE, UK. Electronic address: Jonathan.richenberg@nhs.net.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH